Hepatitis B vaccine - Celldex Therapeutics Inc
Alternative Names: CDX-2101; HepVaxLatest Information Update: 17 Dec 2021
Price :
$50 *
At a glance
- Originator Lorantis
- Developer Celldex Therapeutics Inc
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 03 Apr 2009 No development reported - Preclinical for Hepatitis B in Germany (Parenteral)
- 12 Oct 2005 Lorantis has been acquired by Celldex Therapeutics
- 25 Jul 2003 Preclinical trials in Hepatitis B treatment in Germany (unspecified route)